Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses.
We have previously shown that SSYA10-001 blocks severe acute respiratory syndrome coronavirus (SARS-CoV) replication by inhibiting SARS-CoV helicase (nsp13). Here, we show that SSYA10-001 also inhibits replication of two other coronaviruses, mouse hepatitis virus (MHV) and Middle Eastern respiratory syndrome coronavirus (MERS-CoV). A putative binding pocket for SSYA10-001 was identified and shown to be similar in SARS-CoV, MERS-CoV, and MHV helicases. These studies show that it is possible to target multiple coronaviruses through broad-spectrum inhibitors.
Christopher Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
Adeyemi O
AO
Adedeji
Christopher Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
Kamalendra
K
Singh
Christopher Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
Ademola
A
Kassim
Department of Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Christopher M
CM
Coleman
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Ruth
R
Elliott
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Susan R
SR
Weiss
Department of Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Matthew B
MB
Frieman
Christopher Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA Department of Biochemistry, University of Missouri, Columbia, Missouri, USA sarafianoss@missouri.edu.
Stefan G
SG
Sarafianos
D000595:Amino Acid Sequence; D000818:Animals; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D001665:Binding Sites; D002460:Cell Line; D002522:Chlorocebus aethiops; D004265:DNA Helicases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts / Q000187:drug effects / Q000473:pathology / Q000821:virology; D006801:Humans; D020128:Inhibitory Concentration 50; D051379:Mice; D065207:Middle East Respiratory Syndrome Coronavirus / Q000187:drug effects* / Q000502:physiology; D062105:Molecular Docking Simulation; D008969:Molecular Sequence Data; D006517:Murine hepatitis virus / Q000187:drug effects* / Q000502:physiology; D011485:Protein Binding; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects* / Q000502:physiology; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid; D014230:Triazoles / Q000737:chemistry / Q000494:pharmacology*; D014709:Vero Cells; D014764:Viral Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; C000601132:SSYA10-001; D014230:Triazoles; D014764:Viral Proteins; D004265:DNA Helicases